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To evaluate prevalence, clinical characteristics, and predictors of pain, depression, and their
impact on the quality of life (QoL) in a large neuromyelitis optica spectrum disorder
(NMOSD) cohort.
Methods
We included 166 patients with aquaporin-4–seropositive NMOSD from 13 tertiary referral
centers. Patients received questionnaires on demographic and clinical characteristics, Pain-
Detect, short form of Brief Pain Inventory, Beck Depression Inventory–II, and Short Form 36
Health Survey.
Results
One hundred twenty-five (75.3%) patients suffered from chronic NMOSD-associated pain. Of
these, 65.9% had neuropathic pain, 68.8% reported spasticity-associated pain and 26.4% painful
tonic spasms. Number of previous myelitis attacks (OR = 1.27, p = 0.018) and involved upper
thoracic segments (OR = 1.31, p = 0.018) were the only predictive factors for chronic pain. The
latter was specifically associated with spasticity-associated pain (OR = 1.36, p = 0.002). More
than a third (39.8%) suffered from depression, which was moderate to severe in 51.5%. Pain
severity (OR = 1.81, p < 0.001) and especially neuropathic character (OR = 3.44, p < 0.001)
were associated with depression. Pain severity and walking impairment explained 53.9% of the
physical QoL variability, while depression and walking impairment 39.7% of the mental QoL
variability. No specific medication was given to 70.6% of patients with moderate or severe
depression and 42.5% of those with neuropathic pain. Two-thirds (64.2%) of patients with
symptomatic treatment still reported moderate to severe pain.
From the Department of Neurology (I.A., D.R., E.H., K.H., R.G., I.K.), St. Josef-Hospital, Ruhr-University Bochum, Germany; Department of Neurology (I.A.), Sechenov First Moscow
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France; Aix Marseille Université (J.-P.S.), CRMBM, CNRS UMR 7339, Marseille, France; Department of Neurology (M.S.), University of Ulm, Germany; Münster Department of Neurology
with Institute of Translational Neurology (L.K., M.P.), University Hospital Münster, Germany; Department of Neurology (H.L.P., M.S.W.), UniversityMedical Center, Göttingen, Germany;
Department of Neurology (M.P.), Otto-von-Guericke University, Magdeburg, Germany; Department of Neurology (P.S.R.), Medical University of Vienna, Austria; Neuroimmunology
Section (P.S.R.), Department of Neurology, University of Rostock, Germany; Department of Neurology (A.B.), School of Medicine, Technical University of Munich, Germany; Charité-
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Conclusions
Myelitis episodes involving upper thoracic segments are main drivers of pain in NMOSD. Although pain intensity was lower
than in previous studies, pain and depression remain undertreated and strongly affect QoL. Interventional studies on targeted
treatment strategies for pain are urgently needed in NMOSD.
Neuromyelitis optica spectrum disorder (NMOSD) is an
autoimmune inflammatory disorder that primarily affects the
visual pathway, brain, and spinal cord.1,2 Autoantibodies tar-
geting aquaporin-4 (AQP4) are present in the majority of
patients and proved to be pathogenic in animal models.3,4
NMOSD attacks often do not fully recover and residual
clinical deficits remain in >75% of attacks.5,6 Beside severe
physical impairments, NMOSD can go along with symptoms
like chronic pain, cognitive deficits, and depression.7,8
Spinal pain, girdle-like dysesthesia, and painful spasms were
noted already in earliest disease descriptions in the 18th century.9
Nowadays, it has become clear that pain is a frequent and one of
the most disabling symptoms of NMOSD.8,10-15 Chronic
NMOSD-associated pain affects quality of life (QoL), with pain
severity being the most important predictive factor.10,12,13,15
Possible underlying mechanisms include damage of the central
nociceptive and antinociceptive pathways, particularly the dorsal
horn of the spinal cord and the dorsal root entry zone, auto-
nomic thoracolumbar nuclei, the periaqueductal gray, and hy-
pothalamus. Excessive levels of extracellular glutamate and
increase of proinflammatory factors, such as interleukin (IL)-6,
IL-17, and C5a, can additionally facilitate nociceptive process-
ing.16 Glutamate excitotoxicity can cause an imbalance between
excitation and inhibition in nociceptive system, resulting in
spontaneous neuropathic pain.
Because of the rarity of NMOSD, most previous studies of
pain were relatively small.10,11,17 Moreover, several studies
included a mixed population of AQP4-IgG–seropositive and
–seronegative patients,10-13,15 whereas recent clinical trials
clearly indicate that pathogenetic mechanisms are different in
these forms.18 Accordingly, data on clinical and paraclinical
predictors of pain as well as its association with depression
and effects on QoL remain limited.
We sought to investigate clinical characteristics, risk factors, and
impact of pain syndromes and depression in a Central European
cohort of patients with AQP4-IgG–seropositive NMOSD. Fur-
thermore, we wanted to evaluate the efficacy of immunotherapies
and symptomatic treatment for both conditions and search for a
short screening question to detect patients with disabling pain.
Methods
Patients
We performed an exploratory, questionnaire-based, cross-
sectional study in the years 2017–2019. Patients with AQP4-
IgG–seropositive NMOSD according to IPND criteria19 were
identified through the registry of the German Neuromyelitis
Optica Study Group (NEMOS, nemos-net.de). Details on the
registry, participating centers, and data collection, quality and
processing can be found in previous publications.5,6 Inclusion
criteria were (1) age over 18 years and (2) positive AQP4-
IgG, confirmed in a cell-based assay. Patients with known
relevant cognitive deficits were excluded. All patients were in
remission during the study. Clinical data, including Expanded
Disability Status Scale (EDSS), therapies, and localization of
spinal lesions in cervical and thoracic segments on MRI, were
retrieved from the NEMOS database or local patient records.
Data on current pain, depression, walking, and visual im-
pairment and QoL were captured by self-reporting ques-
tionnaires. Patients were instructed to report on NMOSD-
associated pain syndromes only.
Questionnaires
Current pain was assessed using the PainDetect questionnaire
(PDQ),20 the short form of the Brief Pain Inventory (SF-
BPI), and the McGill Pain Questionnaire Short Form (MPQ-
SF).21 The questions of the SF-BPI consist of 2 categories: (1)
pain severity (present, highest, least, and average pain) based
on a Numeric Rating Scale (NRS) from 0 (no pain) to 10
(worst pain imaginable) within the last week. The pain se-
verity index score represents the average score of these 4 pain
intensity scores. (2) Seven domains of pain-related in-
terference in activity of daily living (ADL), rated from of 0 (no
interference) to 10 (complete interference): general activity,
mood, walking ability, working ability, relations with other
people, sleep, and enjoyment of life. The PDQ was adminis-
tered to evaluate pain localization and discriminate between
definite neuropathic (PDQ score >18), probable neuropathic
(PDQ score 13–18), and nociceptive pain (PDQ score <13).
The MPQ-SF consists of 15 words, describing sensory (11
words) and affective (4 words) components of pain. Patients
rate their intensity as 0 = none, 1 = mild, 2 = moderate, or 3 =
Glossary
ADL = activity of daily living; BDI = Beck Depression Inventory; EDSS = Expanded Disability Status Scale; MCS = mental
component summary;MPQ-SF =McGill Pain Questionnaire Short Form;NMOSD = neuromyelitis optica spectrum disorder;
PDQ = PainDetect questionnaire; PTS = painful tonic spasm.
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severe. Three pain scores are derived from the sum of the rank
values: (1) sensory, (2) affective, and (3) total descriptors.
Painful tonic spasms (PTSs) were assessed asking the patient
whether they experienced recurrent attacks or short episodes
(duration <1 minute) of localized muscle spasms, accompa-
nied by severe pain.
Depression was evaluated using Beck Depression Inventory II
(BDI-II), scored from 0 (best) to 63 (worst) (<9: no de-
pressive affect; 9–13: minimal mood disturbance; 14–20: mild
depression, 21–28: moderate depression; and ≥29: severe de-
pression). Clinically relevant depression was defined by a score
of ≥14. Health-related QoL was measured with the SF-36
questionnaire, consisting of 36 items in 8 subscales. A Physical
Component Summary (PCS) and a Mental Component
Summary (MCS) were calculated using norm-based attaining
values from 0 (worst) to 100 (best).
Standard Protocol Approvals, Registrations,
and Patient Consents
Ethics approval was obtained from the Institutional Review
Board of the Ruhr-University Bochum (#15-5534). Ethics
approval of the NEMOS registry was obtained in participating
centers locally. Patients provided written informed consent.
The study was performed according to International Con-
ference on Harmonization/Good Clinical Practice and cur-
rent legal requirements.
Statistical Analysis
Descriptive statistics were used to describe sample data. Com-
parisons of interval-scaled variables were performed using the
2-sample t test for normally distributed variables, the Mann-
Whitney-Wilcoxon rank-sum test for nonparametric or ordinal-
scaled variables, and the χ2 test for categorical variables. We used
binary logistic regression to evaluate factors associated with
overall pain (yes vs no) as well as neuropathic (neuropathic vs
nociceptive pain) and spasticity-related pain (spasticity-associated
vs other [non–spasticity-associated] pain) as dependent variables.
The following independent variables were included into the lo-
gistic model: sex, age, EDSS, disease duration, AQP4-IgG titer,
overall number of previous relapses, number of myelitis attacks,
and number of involved spinal segments. Concerning depressive
state, sex, age, disease duration, walking, and visual impairment
were included into analysis. A multiple robust regression model
with backward feature selection was used to determine predictors
for hrQoL, with PCS and MCS composites as dependent vari-
ables and age, sex, disease duration, walking and visual impair-
ment, pain severity, and Beck depression index as independent
variables.22 To check for correlations between pain intensity and
different aspects of ADL, we performed the Spearman correlation
test. This study was an exploratory pilot study, with no a priori
sample size calculation. For the same reason, statistical signifi-
cance was set at p < 0.05 without adjustment for multiple testing.
Numerical calculations were performed by SPSS Statistics, Ver-
sion 25, SPSS Inc., an IBM Company, and The R Project for
Statistical Computing, Version 3.4.0 (2017-04-21), The R
Foundation for Statistical Computing.
Data Availability
Anonymized data not published within this article are avail-
able on reasonable request from any qualified investigator
within 5 years after publication.
Results
Demographic and Clinical Characteristics
Thirteen tertiary referral NEMOS centers participated in the
study, and 172 questionnaires were sent back to the reading
center in Bochum for analysis. The response rate was 83.1%
(data on response rate available for 7 centers, addressing









Age, y 51.7 (13.4)
Disease duration, y 9.1 (8.1)
ARR 1.1 (1.6)
Total number of ON episodes since
onset
2.2 (4.1)
Total number of myelitis episodes since
onset
4.6 (7.4)
Total number of involved spinal
segments
5.3 (4.1)
No. of involved cervical segments 2.2 (2.1)
No. of involved thoracic segments 3.2 (3.3)
AQP4-IgG titer (CBA) 1:100 (1:10–1:25.600)




Anti-IL6 therapy (tocilizumab N = 11, SA237 N = 1) 7.2%, 12
Mycophenolate mofetil 4.8%, 8
Other therapies (methotrexate N = 2, prednisone N = 2,
mitoxantrone N = 2, IVIg N = 1, glatiramer acetate N = 1,
cyclosporin N = 1)
5.4%, 9
Prednisone as add-on therapy 10.2%, 17
No immunotherapy 7.8%, 13
Abbreviations: ARR = annualized relapse rate; AQP4 = aquaporin-4; CBA =
cell-based assay; EDSS = Expanded Disability Status Scale; F:M = female:
male; ON = optic neuritis.
a Five in combination with oral immunosuppressive agents.
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71.1% of respondents). Data of 6 questionnaires were in-
sufficient and had to be excluded. In total, 166 patients with
AQP4-IgG–seropositive NMOSD (148 female and 18 male)
were included. Main demographic and clinical characteristics
are described in table 1. Most patients in the cohort had a
history of myelitis (152; 91.6%) or optic neuritis (114;
68.7%), 95 (57.2%) of both myelitis and optic neuritis. Data
on the last available spinal MRI were available for 143 of 166
patients (130 of 152 with a history of myelitis) and demon-
strated a 2-peak distribution (C2-C6 and Th2-Th7) of lesion
location (figure 1). Eleven of 21 patients without visible spinal
lesions had a history of myelitis. Six patients only had a relapse
in the previous 6 months.
Overall Pain Prevalence and
Main Characteristics
Overall, 125 (75.3%) patients suffered from chronic NMOSD-
associated pain. The intensity ofNMOSD-associated chronic pain
wasmoderate to severe in 55.2%of pain sufferers (figure 2A). Pain
wasmainly described as aching (90.4%), tender (76.8%), stabbing
(68.8%), or burning (66.4%) on sensory dimensions and tiring-
exhausting (68.0%) on affective dimension. Most prevalent were
chronic pain without painless periods (n = 77, 61.6%). Isolated or
overlapping pain attacks reported 48 (38.4%) and 40 (32.0%)
patients accordingly (figure 2B). Every second patient (n = 88,
53%) reported pain as a symptom of the last relapse.
Prevalence of Different Types of Pain
One-third of pain sufferers had nociceptive (n = 39, 30.7%),
probable neuropathic (n = 43, 33.9%), or definite neuropathic
pain (n = 40, 31.5%) each; in 3 patients, the type of pain could
not be identified (figure 2C). Pain was most often localized in
legs (72.8%, in two-thirds of cases bilateral), followed by arms
(48.8%, in half of cases bilateral), trunk (34.4%), and neck/
head region (27.2%). Most intense pain were reported by
patients with pain localization in the trunk (4.9 ± 1.7 vs 3.3 ±
2.2, p < 0.05) or legs (4.1 ± 2.2 vs 3.2 ± 2.0, p < 0.05). Trunk
pains were more often of definite neuropathic than of prob-
able neuropathic or nociceptive character (55.8% vs 27.9% vs
16.3%; p < 0.05), whereas no changes were found for pains in
other regions of the body.
Two-thirds of the pain sufferers reported spasticity-associated
pain (n = 86, 68.8%) (figure 2D). It was significantly more
prevalent in patients with nociceptive than neuropathic pain
(87.8% vs 55.8%, p = 0.02). Thirty-three patients (26.4%) had
short-lasting PTS, mostly in the legs (n = 28, 84.8%) and
rarely in the arms (n = 6, 18.2%). These patients reported
approximately 5 PTS episodes a day (4.9 ± 6.4), with a range
of 26 attacks per day to 1 per week.
Episodes of Myelitis Involving Upper Thoracic
Segments Are Associated With Chronic Pain
Chronic pain was not associated with age, sex, AQP4-IgG
titer, disease duration, overall disability (EDSS), or depressive
state (BDI > 14). However, the number of previous attacks
was significantly associated with the occurrence of pain (OR
1.12 [1.02–1.21], p = 0.020). More detailed analysis revealed
that the total number of episodes of myelitis (OR 1.27
[1.05–1.57], p = 0.018), but not the number of optic neuritis
(OR 1.02 [0.92–1.13], p = 0.716), was relevant. There was no
association of pain prevalence or severity with the presence or
any specific localization of persistent spinal lesions (table 2).
However, we found an association of the number of involved
spinal segments with pain (OR 1.14 [1.03–1.28], p = 0.024).
Moreover, the number of lesions in the upper 6 thoracic
segments only (but not in cervical or lower thoracic lesions)
was associated with the risk of having pain in general (OR 1.31
[1.01–1.63], p = 0.018) and was the only specific factor in-
creasing the risk of spasticity-associated pain among pain
sufferers (OR 1.36 [1.10–1.67], p = 0.002). We could not find
any specific factors associated with short-lasting PTS. De-
pressive state was the only factor strongly associated with
neuropathic pain (OR 3.44 [1.35–8.80], p = 0.001).
Figure 1 Distribution of Persistent Spinal Lesions in Cervical and Thoracic Segments
Shown is the frequency (%) of patients (total n = 143) with a spinal lesion on MRI at the appropriate level.
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Pain Severity Strongly Correlates With
Reduction of Activities of Daily Living
Effects of pain on ADL are given in table 3. Correlation
analysis revealed a strong correlation of pain severity with
general activity (rho = 0.69, p < 0.001) and sleep (rho = 0.61,
p < 0.001), followed by mood (rho = 0.55, p < 0.001), walking
ability (rho = 0.54, p < 0.001), normal work (rho = 0.52, p <
0.001), enjoyment of life (rho = 0.50, p < 0.001), and relations
(rho = 0.46, p < 0.001). We observed an even stronger neg-
ative effect of definite neuropathic pain on all evaluated ADL
aspects compared with nociceptive pain.
Chronic Pain But Not Physical Impairment Is
Associated With Depression in NMOSD
Sixty-six (39.8%) patients suffered from depression: mild in
32 (19.3%), moderate in 21 (11.6%), and severe in 13 (7.8%)
Figure 2 Main Characteristics of the NMOSD-Associated Pain
(A) Intensity, (B) temporal patterns (a. continuous pain with slight fluctuations; b. continuous pain with pain attacks; c. pain attacks with painless periods; d.
pain attacks without painless periods), and (C and D) character of pain. Values of pain intensity are given in median, interquartile range, and minimal and
maximal values. Prevalence is given in (%). NMOSD = neuromyelitis optica spectrum disorder. NRS = Numeric Rating Scale, PTS = painful tonic spasm.
Table 2 Prevalence and Severity of Pain in 143 Patients With Spinal Lesions of Different Localizations
Localization of spinal lesions Prevalence of pain BPI-PSI PainDetect score
No persistent lesions (N = 21) 68.2% (N = 15)a 3.6 ± 2.4 13.5 ± 5.1
Isolated cervical lesions (N = 27) 66.7% (N = 18) 3.4 ± 1.9 15.0 ± 7.5
Isolated thoracic lesions (N = 33) 81.8% (N = 27) 4.3 ± 2.2 17.4 ± 6.7
Cervicothoracic lesions (N = 62) 77.0% (N = 47) 3.7 ± 2.2 16.2 ± 6.6
Abbreviation: BPI-PSI = Pain Severity Index of Brief Pain Inventory.
BPI-PSI and PainDetect Score values are given in mean ± SD for pain sufferers. No significant differences were found.
a Seven of 15 patients had at least 1 myelitis episode in the history.
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cases. There was no association between a depressive state
(BDI > 14) and age, sex, or disease duration. Univariate re-
gression analyses revealed pain severity as well as walking and
visual impairment to be associated with depressive state. In
the multiple logistic regression analysis, pain intensity (OR
1.53 [1.22–1.91], p < 0.001) remained the only factor in-
dependently associated with a depressive state.
Pain, Depression, andWalking Impairment Are
3 Main QoL Predictors
The physical but not the mental composite subscale was
significantly lower in pain sufferers (table 4). Among pain
sufferers, patients with definite neuropathic pain had signifi-
cantly lower scores in both SF-36 composites comparing to
those with nociceptive pain. Multivariate regression analysis
identified pain severity (p < 0.001) and walking impairment
(p < 0.001) as 2 independent predictors explaining 53.9% of
the physical QoL composite variability. Depression measured
by the BDI score (p < 0.001) and to a lesser extent walking
impairment (p = 0.043) determined 39.7% of the mental QoL
composite variability.
Symptomatic Pain Treatment Is Insufficiently
Effective in Real-Life Practice
Two-thirds (n = 81, 64.8%) of the 125 pain sufferers took
pain medications, antidepressants, or both. Most of them
took 1 (n = 44, 35.2%) or 2 (n = 25, 20.0%) pain medica-
tions. Nine patients (7.2%) had 3 different pain medications,
and 3 patients had 4, 5, and 6 medications each. Pain med-
ication included nonopioid analgesics (including non-
steroidal anti-inflammatory drugs) (n = 47, 37.6%),
antiepileptic medications for neuropathic pain (including
gabapentin, pregabalin, carbamazepine, and oxcarbazepine)
(n = 51, 40.8%), and opioids (n = 13, 10.4%). Antidepres-
sants were taken by 21 (16.8%) pain sufferers. Surprisingly,
only one-third (n = 10, 29.4%) of those with at least mod-
erate depression (BDI > 20) took antidepressants. Seven of
10 suffered from pain with a median pain intensity of 5.0
(2.0–8.0), so that antidepressant medication could be a
component of pain therapy.
Patients with definite neuropathic pain took symptomatic
therapy significantly more often compared with those with
nociceptive pain (85.0% vs 51.3%, p = 0.002, table 5). How-
ever, among the 40 patients with neuropathic pain, only 23
(57.5%) took specific medications. Retrospectively, patients
reported a substantial reduction of the pain intensity through
pain medications; median 60% (range 0–100) in all patients,
50% (0–100) in those with definite neuropathic pain, 65%
(0–100) in those with nociceptive pain. Only 4 patients
(4.9%) were pain-free, and 25 patients (30.9%) reported mild
pain. Most patients still reported moderate (n = 41, 50.6%) or
severe (n = 11, 13.6%) pain despite symptomatic treatment.
Only 28.8% of those with spasticity-associated pain received
antispastic medications.
Effects of Immunotherapies on
Pain Experience
There was no difference in terms of pain prevalence or intensity
in patients with different immunotherapies. Retrospectively,
39.5% of pain sufferers reported improvement of pain after start
of immunotherapy: 28 of 75 (37.3%) under rituximab, 6 of 15
(40.0%) under azathioprine, 2 of 6 (33.3%) under mycophe-
nolate mofetil, and 6 of 9 (66.7%) under tocilizumab.
Pain Pattern Question Can Be an Effective
Screening Tool
Finally, we searched for a short screening question allowing
identification of those patients most affected by pain in
NMOSD. We used the 4 pain patterns from the PDQ (table
6). Patients suffering from pain attacks without painless in-
tervals (patterns 2 and 4) had significantly more intense pains
and a significantly lower physical QoL component. Moreover,
the majority of those with pattern 4 suffered frommoderate or
severe depression (87.5%) and neuropathic pain (62.5%) and
had lower mental QoL.
Discussion
We evaluated a large cohort of patients with AQP4-
IgG–seropositive NMOSD for pain and comorbid de-
pression. As much as 75.3% of all patients suffered from
NMOSD-associated chronic pain, in line with previously
reported 80%–86% in smaller studies from other geographic
areas.10-12,14,23 The majority of patients reported continuous
pain, often superimposed by pain attacks. Pain localization
was in the legs in 3/4 and around the trunk and in arms in 1/2
each. Overall pain intensity was lower in our cohort compared
with previous studies conducted a decade ago,10-12 and only 10%















4.6 ± 2.6 5.7 ± 2.3a 3.6 ± 2.6
Mood 4.0 ± 3.1 5.4 ± 2.9a 3.0 ± 2.7
Walking
ability
4.7 ± 3.4 5.8 ± 3.2a 3.2 ± 3.1
Normal
work
5.0 ± 3.2 6.6 ± 2.7a 3.9 ± 3.1
Relations 3.4 ± 3.3 5.0 ± 3.2a 2.4 ± 2.8
Sleep 4.1 ± 3.2 5.8 ± 3.0a 2.8 ± 2.7
Enjoyment
of life
3.7 ± 3.3 5.1 ± 3.2a 2.8 ± 2.9
Abbreviation: ADL = activity of daily living.
Values are given in mean ± SD.
a p < 0.001, t test.
6 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 3 | May 2021 Neurology.org/NN
suffered from severe pain. Both median EDSS and the total
number of involved spinal segments were lower than in previous
studies. Less aggressive disease course, probably due to earlier
diagnosis and/or more effective immunotherapy, could explain
these differences. Indeed, two-thirds of our patients received rit-
uximab, and about 40% reported reduction of pain under current
immunotherapy. A positive selection bias could be another pos-
sible explanation. No data on questionnaire response rates have
been reported in 2 of 3 abovementioned smaller surveys.11,12 Of
interest, similar to one of the previous studies, we achieved a
relative high response rate and pain severity was very similar in
both studies (3.6 ± 2.8 other study; 3.8 ± 2.1 our cohort).10
Using the PDQ, 24% of our patients had definite neuropathic
pain and further 26% signs of possible neuropathic pain. Two
previous studies reported a significantly higher prevalence of
neuropathic pain, 62% and 86%, respectively, based on the
Douleur Neuropathique 4 questionnaire and less clearly de-
fined clinical criteria.12,23 In a recent PainDetect-based small
study, definite neuropathic pain was present in 7% only.14
We were able to identify several predictors of pain in our
cohort. The number of myelitis episodes and the extent of
spinal cord lesions independently contributed to the risk of
NMOSD-associated pain. Previous smaller studies
demonstrated contradictory results.11,12,23 Although a correla-
tion between pain intensity and an overall length of the spinal
lesions was reported, this could not be confirmed in another
study.11,12 It is likely that different severity and location (both
sagittal and axial) of injuries have different effects on pain per-
ception. In contrast to a recentUK study,23 we could not confirm
a protective effect of persistent cervical lesions; however, injuries
in the upper thoracic (but not cervical or lower thoracic) seg-
ments were critical for development of chronic pain. Previously,
a causative relationship between upper thoracic lesions and
neuropathic pain was postulated.23 As known, patients with
spinal lesions develop both neuropathic and nociceptive pain.24
To evaluate a link between spinal lesions and neuropathic pain,
we compared patients with a definite nociceptive and definite
neuropathic pain. We could not confirm a specific association of
the latter with any extent or any precise sagittal lesions location.
In contrast, the number of involved upper thoracic segments was
significantly associated with the risk of spasticity-associated pain,
observed in two-thirds of pain sufferers. Spasticity was one of the
main mechanisms underlying nociceptive NMOSD-associated
pain in our cohort, being present in almost 90% of these patients.
Similar to previous studies, we found that approximately 20%
of all respondents suffered from short-lasting PTSs.17 Despite
a previously supported association of PTS to incompletely


























47.7 ± 36.0 63.3 ± 39.1 43.4 ± 33.7a 52.1 ± 36.9 36.1 ± 28.6b 59.6 ± 35.2 30.7 ± 29.5c
SF-36
RP
41.0 ± 41.3 44.7 ± 24.3 36.9 ± 38.8a 39.1 ± 37.1 28.9 ± 38.7 53.6 ± 41.6 22.2 ± 33.0c
SF-36
BP
52.2 ± 30.1 78.1 ± 32.9 44.7 ± 24.3a 54.1 ± 23.6 33.9 ± 20.1b 59.9 ± 27.2 41.6 ± 30.6c
SF-36
GH
44.1 ± 20.4 51.7 ± 19.5 41.8 ± 20.2a 46.5 ± 20.1 36.6 ± 15.8b 51.3 ± 20.2 33.1 ± 15.3c
SF-36
VT
43.1 ± 21.9 52.3 ± 20.6 40.3 ± 21.7a 45.7 ± 21.3 31.2 ± 18.7b 53.8 ± 18.6 27.0 ± 15.8c
SF-36
SF
66.6 ± 29.7 77.3 ± 25.8 63.6 ± 30.1a 68.3 ± 27.6 57.8 ± 30.2 77.7 ± 25.7 50.5 ± 27.5c
SF-36
RE
68.5 ± 42.0 81.9 ± 34.6 65.3 ± 43.0a 76.9 ± 37.6 52.1 ± 45.8b 82.3 ± 35.2 47.9 ± 43.2c
SF-36
MH
65.5 ± 20.9 68.0 ± 18.5 64.7 ± 21.7 70.7 ± 20.9 56.7 ± 24,3b 76.8 ± 13.6 48.6 ± 18.5c
SF-36
PCS
34.7 ± 12.2 43.9 ± 12.5 32.2 ± 10.8a 34.4 ± 10.9 29.6 ± 9.3b 38.1 ± 12.0 29.6 ± 10.7c
SF-36
MCS
48.0 ± 11.6 49.2 ± 10.2 47.6 ± 12.0 50.5 ± 12.2 43.1 ± 11.6b 53.2 ± 8.0 40.0 ± 11.6c
Abbreviations: BP = bodily pain; GH = general health; MCS = mental component summary; NMOSD = neuromyelitis optica spectrum disorder; PF = physical
functioning; QOL = quality of life; RE = role-emotional; RP = role-physical; SF = social functioning; SF-36 = short form 36 and its different domains; VT = vitality.
Values are given in mean ± SD.
a Significant lower comparing to patients without pain.
b Significant lower comparing to patients with a nociceptive pain.
c Significant lower comparing to patients without a depressive state, t test.
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remyelinated spinal lesions, we could not confirm this finding
either. In MS, PTSs are supposed to be associated with tha-
lamocortical lesions.25,26
The 19% prevalence of moderate to severe depression in our
cohort was lower compared with an earlier reported 28% in
NMOSD.27 Similar to previous studies, only pain severity but
not disability, disease activity, or any other demographic pa-
rameter was associated with depression. Depression was the
only factor associated with neuropathic but not nociceptive
pain; however, identification of causative relationships be-
tween these conditions is impossible in a cross-sectional
study. Bidirectional relationships between depression and
neuropathic pain are well known and especially in in-
flammatory diseases share common underlying mecha-
nisms.28 It is noteworthy that a specific direct link between
NMOSD and depression has been supposed in experimental
studies: AQP4 deficiency itself results in a decreased hippo-
campal neurogenesis, which could contribute to the patho-
genesis of depression.29
Despite being mild to moderate, pain and depression can have
enormous negative effects on patient’s life. Pain markedly
reduced all aspects of ADL. Pain intensity and walking im-
pairment were 2 main factors independently associated with
lower physical QoL, whereas the latter and depression had an
impact on the mental QoL. Comparing patients with noci-
ceptive and neuropathic pain, the latter had significantly lower
ADL as well as both lower physical and mental composites of
QoL. Of interest, 2 temporal pain patterns (persistent pain
with pain attacks and pain attacks with pain between them)
were associated with a markedly higher pain intensity, de-
pression prevalence, and lower QoL. This simple image-based
question allowing prompt identification of most disabled
patients might be useful for pain screening in NMOSD.
In previous NMOSD studies, an insufficient symptomatic
therapy has been reported.15 In our cohort, 65% received pain
medications, and two-thirds of them reported a significant
pain relief. Despite multiple medications, pain intensity
mostly remained moderate, and only a minority of patients




Patients with definite nociceptive pain
(N = 39)
Patients with definite neuropathic pain
(N = 40)
Symptomatic therapy 63.8% (81) 51.3% (20) 85% (34)
Pain reduction by symptomatic
therapy in the last week (median,
min–max)
60% (0–100) 65% (0–100) 50% (0–100)
Mean pain intensity 4.3 ± 2.0 3.3 ± 1.6 5.0 ± 2.0a
Pain-free 4 (4.9%) 1 (5.0%) 0
Mild pain (1–3 NRS) 25 (30.9%) 10 (50.0%) 9 (26.5%)
Moderate pain (4–6 NRS) 41 (50.6%) 9 (45.0%) 15 (44.1%)
Severe pain (>6 NRS) 11 (13.6%) 0 10 (29.4%)
Abbreviation: NRS = Numeric Rating Scale.
If not otherwise specified, values are given inmean ± SD. Patients with ambiguous pain character (probable neuropathic or nociceptive) were excluded from
this analysis.
a p < 0.001, t test.












Continuous pain with slight
fluctuations
3.9 ± 2.0 22.2% 40.5% 33.2 ± 9.6 47.9 ±
11.7
Continuous pain with pain
attacks
4.8 ± 2.0a 35.5% 43.8% 27.9 ± 9.3a 48.7 ±
10.9
Pain attacks with painless
periods
3.0 ± 2.0 35.4% 33.3% 34.0 ± 11.1 47.9 ±
12.4
Pain attacks without painless
periods
5.6 ± 1.8a 62.5%b 87.5%b 24.9 ± 9.8a 38.6 ±
13.4b
Abbreviations: QOL = quality of life; BDI = Beck Depression Inventory II.
Values are given in mean ± SD.
a Significant difference vs patterns 1 and 3; ANOVA
b Significant difference vs patterns 1, 2, and 3; ANOVA or Fisher exact test, respectively.
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was pain-free. Insufficient on-target medication could be one
of the reasons: antispastic medications were administered in
only 29% of those with a spasticity-associated pain and only
58% of patients with neuropathic pain had specific treatment.
Compared with pain, depression was less often adequately
treated. Twenty-nine percent of those with moderate to se-
vere depression received antidepressants. The actual number
of patients receiving adequate antidepressant pharmacother-
apy is probably even lower, as at least in some of them, an-
tidepressants were administered as a part of pain therapy.
The strengths of our study are inclusion of a relatively large
cohort of purely AQP4-IgG–seropositive NMOSD patients and
the definition of clinical and paraclinical predictors of pain as well
as its association with depression and effects on QoL. There are
also limitations. Because we only asked for pharmacologic treat-
ments, no information about nonpharmacologic pain therapies
and psychotherapy is available. Transcutaneous electric nerve
stimulation was recently reported to reduce persistent central
neuropathic pain inNMOSD.30 BecauseMRI data were retrieved
by record review, we could not perform a precise analysis of
transverse localization and size of the spinal lesions. In addition,
no brain MRI was performed to evaluate central nociceptive
pathways. There were no sufficient data on lumbar MRI, rarely
involved by seropositive NMOSD. The analysis of lesion exten-
sion in the acute phase of myelitis could be also promising, as
some injured foci become invisible afterward. Moreover, pro-
spective evaluation of the type and severity of pain in the first 6
months after acutemyelitis could be helpful for precise analysis of
possible underlying mechanisms. A relatively high proportion of
pain sufferers (35%) took no pain medications during the study.
It remains unclear whether the medications have not been ad-
ministered due to low pain intensity or stopped due to low
efficacy and side effects. It would be important to address this
point in further studies. Finally, we did not perform an analysis of
fatigue, an important factor influencing depression and QoL.
In conclusion, chronic pain and depression are highly prevalent
and strongly affect QoL and ADL in AQP4-IgG–seropositive
NMOSD. Both conditions remain undertreated and therefore
should be asked for in the diagnostic workup. Pain attacks
without painless periods are typical for NMOSD and have the
most severe impact. Episodes of myelitis involving upper tho-
racic segments are main drivers of pain in NMOSD and should
be prevented and aggressively treated. Adequate immunother-
apy has a beneficial effect on pain experience. Higher awareness
and interventional studies on targeted symptomatic treatment
of neuropathic and spasticity-associated pain, including char-
acteristic and very intense short-lasting PTSs, are warranted and
could change a real-life clinical practice in NMOSD.
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Appendix 2 Coinvestigators
Members of the Neuromyelitis Optica Study Group (NEMOS) are listed
below in alphabetical order.
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Appendix 2 (continued)
Members of the Neuromyelitis Optica Study Group (NEMOS) are listed
below in alphabetical order.













































































































































































Members of the Neuromyelitis Optica Study Group (NEMOS) are listed
below in alphabetical order.































































































































































12 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 3 | May 2021 Neurology.org/NN
References
1. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin
Proc 2017;92(4):663–679.
2. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening.
Curr Opin Neurol 2019;32(3):385–394.
3. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuro-
myelitis optica. PLoS Med 2007;4(4):e133.
4. Hillebrand S, Schanda K, Nigritinou M, et al. Circulating AQP4-specific auto-
antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta
Neuropathol 2019;137(3):467–485.
5. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive
and seronegative neuromyelitis optica: a multicentre study of 175 patients.
J Neuroinflammation 2012;9:14.
6. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks
and 1153 treatment courses. Ann Neurol 2016;79(2):206–216.
7. Moore P, Methley A, Pollard C, et al. Cognitive and psychiatric comorbidities in
neuromyelitis optica. J Neurol Sci 2016;360:4–9.
8. Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder:
patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm 2019;
6(4):e580.
9. Jarius S, Wildemann B. The history of neuromyelitis optica. Part 2: ‘Spinal amaurosis’,
or how it all began. J Neuroinflammation 2019;16(1):280.
10. Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on
quality of life: a cross-sectional study. Neurology 2011;77(7):652–658.
11. Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and
intractable pain. Arch Neurol 2012;69(11):1482–1487.
12. Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects
activities of daily living and quality of life. Mult Scler 2014;20(12):1658–1661.
13. Kong Y, Okoruwa H, Revis J, et al. Pain in patients with transverse myelitis and its
relationship to aquaporin 4 antibody status. J Neurol Sci 2016;368:84–88.
Appendix 2 (continued)
Members of the Neuromyelitis Optica Study Group (NEMOS) are listed
below in alphabetical order.

















































































































































































Members of the Neuromyelitis Optica Study Group (NEMOS) are listed
below in alphabetical order.
































































































Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 3 | May 2021 13
14. Asseyer S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-
positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2018;
4(3):2055217318796684.
15. Hyun JW, Jang H, Yu J, et al. Comparison of neuropathic pain in neuromyelitis optica
spectrum disorder and multiple sclerosis. J Clin Neurol 2020;16(1):124–130.
16. Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica—prevalence,
pathogenesis and therapy. Nat Rev Neurol 2014;10(9):529–536.
17. Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica:
incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012;69(8):
1026–1031.
18. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica
spectrum disorder. N Engl J Med 2019;381(22):2114–2124.
19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic
criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–189.
20. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire
to identify neuropathic components in patients with back pain. Curr Med Res Opin
2006;22(10):1911–1920.
21. Melzack R. The short-form McGill pain questionnaire. Pain 1987;30(2):191–197.
22. Fox J, Weisberg A. An R Companion to Applied Regression. 3rd ed. SAGE Publi-
cations Inc.; 2018.
23. Tackley G, Vecchio D, Hamid S, et al. Chronic neuropathic pain severity is de-
termined by lesion level in aquaporin 4-antibody-positive myelitis. J Neurol Neuro-
surg Psychiatry 2017;88(2):165–169.
24. Muller R, BrinkhofMW, Arnet U, et al. Prevalence and associated factors of pain in the
Swiss spinal cord injury population. Spinal Cord 2017;55(4):346–354.
25. Tuzun E, Akman-Demir G, Eraksoy M. Paroxysmal attacks in multiple sclerosis. Mult
Scler 2001;7(6):402–404.
26. Spissu A, Cannas A, Ferrigno P, et al. Anatomic correlates of painful tonic spasms in
multiple sclerosis. Mov Disord 1999;14(2):331–335.
27. Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression
in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm
2016;3(6):e286.
28. Walker AK, Kavelaars A, Heijnen CJ, et al. Neuroinflammation and comorbidity of
pain and depression. Pharmacol Rev 2014;66(1):80–101.
29. Skucas VA, Mathews IB, Yang J, et al. Impairment of select forms of spatial memory
and neurotrophin-dependent synaptic plasticity by deletion of glial aquaporin-4.
J Neurosci 2011;31(17):6392–6397.
30. Mealy MA, Kozachik SL, Cook LJ, et al. Scrambler therapy improves pain in
neuromyelitis optica: a randomized controlled trial. Neurology 2020;94(18):
e1900–e07.
14 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 3 | May 2021 Neurology.org/NN
DOI 10.1212/NXI.0000000000000985
2021;8; Neurol Neuroimmunol Neuroinflamm 
Ilya Ayzenberg, Daniel Richter, Eugenia Henke, et al. 
Seropositive Patients−Cross-Sectional Study of 166 AQP4 Antibody
 Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A
This information is current as of April 20, 2021
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 




including high resolution figures, can be found at:
References
 http://nn.neurology.org/content/8/3/e985.full.html##ref-list-1

















its entirety can be found online at:




Information about ordering reprints can be found online:
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
